We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

32 hedge funds and large institutions have $22.9M invested in VYNE Therapeutics in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more capital invested

Capital invested by funds: $18.4M → $22.9M (+$4.49M)

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.03% less ownership

Funds ownership: 56.61% → 55.57% (-1%)

3% less funds holding

Funds holding: 33 → 32 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

Holders
32
Holders Change
-1
Holders Change %
-3.03%
% of All Funds
0.46%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
5
Increased
8
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
EAM
Exome Asset Management
New York
+$641K
2
SSA
Schonfeld Strategic Advisors
New York
+$474K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$375K
4
ACM
ADAR1 Capital Management
Texas
+$237K
5
SCM
Silverarc Capital Management
Massachusetts
+$186K

Top Sellers

1
SCM
Soleus Capital Management
Connecticut
-$1.64M
2
AA
AlphaCentric Advisors
Puerto Rico
-$481K
3
FAM
Fred Alger Management
New York
-$140K
4
PCM
Prelude Capital Management
New York
-$50.6K
5
HF
HRT Financial
New York
-$23K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$4.28M – – –
Citadel Advisors
2
Citadel Advisors
Florida
$3.63M – – –
EAM
3
Eventide Asset Management
Massachusetts
$3.13M – – –
PHP
4
Parkman Healthcare Partners
Connecticut
$2.14M – – –
DA
5
DSC Advisors
Illinois
$2.14M – – –
PAI
6
Palo Alto Investors
California
$1.37M – – –
AA
7
AlphaCentric Advisors
Puerto Rico
$1.37M -$481K -223,151 -33%
EAM
8
Exome Asset Management
New York
$1.28M +$641K +297,334 +252%
SSA
9
Schonfeld Strategic Advisors
New York
$675K +$474K +219,800 New
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$538K +$375K +174,107 +13,763%
ACM
11
ADAR1 Capital Management
Texas
$338K +$237K +110,091 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$328K +$26.8K +12,432 +13%
PCM
13
Prelude Capital Management
New York
$290K -$50.6K -23,500 -20%
SCM
14
Silverarc Capital Management
Massachusetts
$265K +$186K +86,383 New
Renaissance Technologies
15
Renaissance Technologies
New York
$247K +$73.7K +34,200 +74%
Vanguard Group
16
Vanguard Group
Pennsylvania
$214K +$43.2K +20,051 +40%
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$185K – – –
BlackRock
18
BlackRock
New York
$137K -$5.77K -2,679 -6%
Northern Trust
19
Northern Trust
Illinois
$113K – – –
SCA
20
STALEY CAPITAL ADVISERS
Pennsylvania
$112K – – –
VF
21
Virtu Financial
New York
$50K +$34.9K +16,199 New
State Street
22
State Street
Massachusetts
$35.8K – – –
Millennium Management
23
Millennium Management
New York
$33.7K -$13.5K -6,283 -36%
Bank of America
24
Bank of America
North Carolina
$6.71K -$1.29K -598 -21%
Morgan Stanley
25
Morgan Stanley
New York
$5.74K -$4.03K -1,868 -50%
1
2

VYNE Hedge Fund Activity: Q1 2024 in Review

32 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2024, worth a combined $22.9M — up 24% from $18.4M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of VYNE and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 8 added.

The largest buyer was Exome Asset Management, adding an estimated $641K. The largest seller was Soleus Capital Management, exiting entirely with an estimated $1.64M sold.

  • 32 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2024, down from 33 in Q4 2023.
  • Funds reported $22.9M of VYNE Therapeutics stock for Q1 2024, up 24% quarter-over-quarter.
  • 5 funds opened new VYNE Therapeutics positions in Q1 2024 and 6 closed out, a net change of -1 holder.
  • The largest VYNE Therapeutics buyer in Q1 2024 was Exome Asset Management, an estimated $641K added.
  • The largest VYNE Therapeutics seller in Q1 2024 was Soleus Capital Management, an estimated $1.64M sold.

Based on aggregated 13F filings for Q1 2024.